60 Use of the Combined Positive Score (CPS) with the companion diagnostic PD-L1 IHC 22C3 pharmDx provides precise evaluation of PD-L1 expression across multiple tumor indications and cutoffs

Similar Items

• 3 External reproducibility of PD-L1 IHC 22C3 pharmDx for colorectal carcinoma specimens at CPS ≥ 1 cutoff
  by: Siena Tabuena-Frolli, et al.
  Published: (2023-11-01)
• 50 External inter-laboratory reproducibility of PD-L1 IHC 22C3 pharmDx (SK006) for biliary tract adenocarcinoma at CPS ≥ 1 and CPS ≥ 10
  by: Siena Tabuena-Frolli, et al.
  Published: (2023-11-01)
• Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
  by: Gilad Vainer, et al.
  Published: (2023-01-01)
• Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer
  by: Michael Crager, et al.
  Published: (2022-11-01)
• 81 Inclusion of PD-L1-expressing tumor cells in the combined positive score algorithm yields superior identification of positive specimens around diagnostic cut-offs across multiple indications
  by: Jonathan Juco, et al.
  Published: (2020-11-01)